GenePOC Instrument, Assays Get CE Mark | GenomeWeb

NEW YORK (GenomeWeb) – GenePOC today announced it has received CE marking for its Revogene instrument and tests for Group B Streptococcus and Clostridium difficile for marketing in Europe and other geographies that recognize the designation.

The Quebec City-based rapid molecular devices firm, which is part of Debiopharm, added that it has completed clinical trials for GBS for the US Food and Drug Administration and expects to start clinical trials for C. difficile by mid-January.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.